Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 1
1975 2
1976 2
1977 1
1978 3
1980 1
1983 1
1985 1
1986 2
1987 1
1990 1
1991 5
1992 2
1993 4
1994 1
1995 4
1996 1
1997 2
1998 3
1999 6
2000 6
2001 4
2002 8
2003 3
2004 3
2005 3
2006 5
2007 3
2008 2
2009 2
2010 5
2011 5
2012 5
2013 5
2014 1
2015 6
2016 5
2017 5
2018 11
2019 7
2020 6
2021 5
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

140 results
Results by year

Citations

2 articles found by citation matching

Search results

Filters applied: . Clear all
Page 1
Genetic basis of hypercholesterolemia in adults.
Saadatagah S, Jose M, Dikilitas O, Alhalabi L, Miller AA, Fan X, Olson JE, Kochan DC, Safarova M, Kullo IJ. Saadatagah S, et al. NPJ Genom Med. 2021 Apr 14;6(1):28. doi: 10.1038/s41525-021-00190-z. NPJ Genom Med. 2021. PMID: 33854068 Free PMC article.
Phenotypic and genetic FH showed poor overlap. Only 26% of those who met the clinical criteria of FH had an identifiable genetic etiology and of those with an identifiable genetic etiology only 12.9% met clinical criteria for FH. Genetic factors explai …
Phenotypic and genetic FH showed poor overlap. Only 26% of those who met the clinical criteria of FH had an identifiable genetic
Author Correction: Genetic basis of hypercholesterolemia in adults.
Saadatagah S, Jose M, Dikilitas O, Alhalabi L, Miller AA, Fan X, Olson JE, Kochan DC, Safarova M, Kullo IJ. Saadatagah S, et al. NPJ Genom Med. 2021 Jun 29;6(1):56. doi: 10.1038/s41525-021-00222-8. NPJ Genom Med. 2021. PMID: 34188061 Free PMC article. No abstract available.
Update of the molecular basis of familial hypercholesterolemia in The Netherlands.
Fouchier SW, Kastelein JJ, Defesche JC. Fouchier SW, et al. Hum Mutat. 2005 Dec;26(6):550-6. doi: 10.1002/humu.20256. Hum Mutat. 2005. PMID: 16250003
The population of patients with ADH was divided into three genetically distinct groups: carriers of an LDLR mutation (FH), carriers of an APOB mutation (FDB), and non-LDLR/non-APOB patients (FH3). No differences were found with regard to untreated cholesterol levels, respo …
The population of patients with ADH was divided into three genetically distinct groups: carriers of an LDLR mutation (FH), carriers o …
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.
Patients were enrolled into six different expansion cohorts (EXP1-6) on the basis of ALK and ROS1 status and previous therapy, and were given lorlatinib 100 mg orally once daily continuously in 21-day cycles. ...Thus, lorlatinib could represent an effective treatmen …
Patients were enrolled into six different expansion cohorts (EXP1-6) on the basis of ALK and ROS1 status and previous therapy, …
Genetic basis and hematologic manifestations of sitosterolemia in a group of Turkish patients.
Kaya Z, Sal E, Yorulmaz A, Hsieh YP, Gülen H, Yıldırım AT, Niu DM, Tekin A. Kaya Z, et al. J Clin Lipidol. 2021 Sep-Oct;15(5):690-698. doi: 10.1016/j.jacl.2021.07.001. Epub 2021 Jul 10. J Clin Lipidol. 2021. PMID: 34304999
METHODS: Seven probands with unexplained hematologic abnormalities and their 13 relatives were enrolled. Sterol levels were measured by gas chromatography and genetic studies were performed using Sanger sequencing. Individuals were diagnosed with sitosterolemia if they wer …
METHODS: Seven probands with unexplained hematologic abnormalities and their 13 relatives were enrolled. Sterol levels were measured by gas …
Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia.
Gill PK, Dron JS, Berberich AJ, Wang J, McIntyre AD, Cao H, Hegele RA. Gill PK, et al. J Clin Lipidol. 2021 Jan-Feb;15(1):79-87. doi: 10.1016/j.jacl.2020.11.006. Epub 2020 Nov 24. J Clin Lipidol. 2021. PMID: 33303402 Free article.
BACKGROUND: Combined hyperlipidemia (CHL) is a common disorder defined by concurrently elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels. Despite decades of study, the genetic basis of CHL remains unclear. OBJECTIVE: To characterize t …
BACKGROUND: Combined hyperlipidemia (CHL) is a common disorder defined by concurrently elevated low-density lipoprotein cholesterol (LDL-C) …
Genetic basis of index patients with familial hypercholesterolemia in Chinese population: mutation spectrum and genotype-phenotype correlation.
Sun D, Zhou BY, Li S, Sun NL, Hua Q, Wu SL, Cao YS, Guo YL, Wu NQ, Zhu CG, Gao Y, Cui CJ, Liu G, Li JJ. Sun D, et al. Lipids Health Dis. 2018 Nov 6;17(1):252. doi: 10.1186/s12944-018-0900-8. Lipids Health Dis. 2018. PMID: 30400955 Free PMC article.
BACKGROUND: Although there have been many reports in the genetics of familial hypercholesterolemia (FH) worldwide, studies in regard of Chinese population are lacking. In this multi-center study, we aim to characterize the genetic spectrum of FH in Chinese po …
BACKGROUND: Although there have been many reports in the genetics of familial hypercholesterolemia (FH) worldwide, studies in …
Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically.
Wang J, Dron JS, Ban MR, Robinson JF, McIntyre AD, Alazzam M, Zhao PJ, Dilliott AA, Cao H, Huff MW, Rhainds D, Low-Kam C, Dubé MP, Lettre G, Tardif JC, Hegele RA. Wang J, et al. Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2439-2445. doi: 10.1161/ATVBAHA.116.308027. Epub 2016 Oct 20. Arterioscler Thromb Vasc Biol. 2016. PMID: 27765764
OBJECTIVE: Next-generation sequencing technology is transforming our understanding of heterozygous familial hypercholesterolemia, including revision of prevalence estimates and attribution of polygenic effects. ...CONCLUSIONS: In a clinically ascertained sample with severe …
OBJECTIVE: Next-generation sequencing technology is transforming our understanding of heterozygous familial hypercholesterolemia, inc …
CADASIL.
Hack RJ, Rutten J, Lesnik Oberstein SAJ. Hack RJ, et al. 2000 Mar 15 [updated 2019 Mar 14]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. 2000 Mar 15 [updated 2019 Mar 14]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. PMID: 20301673 Free Books & Documents. Review.
DIAGNOSIS/TESTING: The diagnosis of CADASIL is established in a proband either by identification of a heterozygous pathogenic variant in NOTCH3 by molecular genetic testing or, if molecular genetic testing is not definitive, by detection of characteristic findings b …
DIAGNOSIS/TESTING: The diagnosis of CADASIL is established in a proband either by identification of a heterozygous pathogenic variant in NOT …
Preliminary spectrum of genetic variants in familial hypercholesterolemia in Argentina.
Bañares VG, Corral P, Medeiros AM, Araujo MB, Lozada A, Bustamante J, Cerretini R, López G, Bourbon M, Schreier LE. Bañares VG, et al. J Clin Lipidol. 2017 Mar-Apr;11(2):524-531. doi: 10.1016/j.jacl.2017.02.007. Epub 2017 Feb 28. J Clin Lipidol. 2017. PMID: 28502510
BACKGROUND: Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated low-density lipoprotein cholesterol and early cardiovascular disease. ...In addition, these data contribute to the understanding of the molecular basis of FH in Arg …
BACKGROUND: Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated low-density lipoprotein cholest …
140 results